You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A Low-Cost, High-Performance Colloidal Quantum Dot MWIR Focal Plane Array

    SBC: SIVANANTHAN LABORATORIES, INC.            Topic: ST13B002

    The primary goal of this proposed effort is to develop mid-wavelength infrared (MWIR) colloidal quantum dot (CQD)-based focal plane arrays (FPAs) to significantly reduce the cost of MWIR photon imagers. In order to realize this goal, it will first be nec

    STTR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency
  2. Wideband Tunable Multiferroic Electronics for Advanced RF Systems (1000-277)

    SBC: SI2 TECHNOLOGIES, INC.            Topic: ST13B003

    SI2 Technologies proposes to design, model, fabricate and transition wideband tunable multiferroic electronics for advanced RF systems including adaptive Radar, software defined radios and other electronic warfare (EW) applications. Combining novel nanost

    STTR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency
  3. Multiferroic Materials for RF Applications

    SBC: Winchester Technologies, LLC            Topic: ST13B003

    Voltage tunable multiferroic materials with strong magnetoelectric coupling provide a unique approach to compact, lightweight and power efficient tunable RF/microwave multiferroic components, such as tunable inductors, filters, phase shifters, etc. The tu

    STTR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency
  4. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government